CLDN2 and gastric carcinoma: Although an increase in claudin-2 expression was found, claudin-2 expression is ubiquitously present in normal and neoplastic tissue, so the benefit of potential therapy against claudin-2 (as in the case of claudin-18.2 in advanced gastric carcinoma [27]) appears to be restricted.